Linagliptin Efficacy on Hyperglycemia, Oxidative Stress, and Inflammation in Gestational Diabetes Mellitus
Article Sidebar
Main Article Content
Abstract
Background: Linagliptin is an anti-diabetic drug that claims no adverse effects and treatment of gestational diabetes mellitus (GDM) demands a safe anti-diabetic medication. Therefore, this study investigates the anti-diabetic efficacy of linagliptin in an induced GDM.
Materials and methods: Thirty-two matured female rats (100 - 200 g) were utilized. Sixteen non-pregnant/diabetic animals were fed with a normal diet and sixteen rats were fed with a high-fat (HFD), mated at the estrous stage in 2:1, and pregnancy was confirmed with a spermatozoa in a vaginal smear. The pregnant rats were intraperitoneally injected with a single dose (30 mg/kgb. wt) of streptozotocin (STZ) to induce GDM. The animals were grouped into 4 groups, 8 rats/groups. Group I: control; Group II: control + 10 mg/kgb.wt linagliptin; Group III: GDM; Group IV: GDM + 10 mg/kgb.wt linagliptin. The animals were sacrificed after 14 days of treatment. Blood samples were collected for biochemical parameters.
Results: Fasting blood glucose (FBG) insulin, glycated hemoglobin (HbA1c), total cholesterol (TC), triglyceride (TG), low-density lipoprotein-cholesterol (LDL-C), malondialdehyde (MDA), interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-alpha (TNF-α) levels significant (p < 0.05) elevated in GDM rats, with significant reduction in high-density lipoprotein-cholesterol (HDL-C), catalase (CAT), superoxide dismutase (SOD) and reduced glutathione (GSH). Linagliptin administration significantly (p < 0.05) decreased the FBG, insulin, HbA1c, TC, TG, LDL-C, MDA, IL-6, IL-1β, and TNF-α and ameliorates the HDL-C, CAT, SOD, and GSH levels significantly.
Conclusion: Linagliptin remarkably showed anti-hyperglycemic, anti-oxidative, and anti-inflammatory properties. Linagliptin could be a promising drug for hyperglycemia treatment during gestation.
Article Details
Copyright (c) 2024 Ajao FO, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Adam S, McIntyre HD, Tsoi KY, Kapur A, Ma RC, Dias S, et al. FIGO Committee on the Impact of Pregnancy on Long-term Health and the FIGO Division of Maternal and Newborn Health. Pregnancy as an opportunity to prevent type 2 diabetes mellitus: FIGO Best Practice Advice. International Journal of Gynaecology and Obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2023; 160:56–67. Available from: https://doi.org/10.1002/ijgo.14537
Omazić J, Viljetić B, Ivić V, Kadivnik M, Zibar L, Müller A, Wagner J. Early markers of gestational diabetes mellitus: what we know and which way forward? Biochemia Medica, 2021; 31(3):030502. Available from: https://doi.org/10.11613/bm.2021.030502
Modzelewski R, Stefanowicz-Rutkowska MM, Matuszewski W, Bandurska S, Tankiewicz EM. Gestational Diabetes Mellitus-Recent Literature Review. Journal of clinical medicine, 2022; 11(19):5736. Available from: https://doi.org/10.3390/jcm11195736
Choudhury AA, Devi Rajeswari V. Gestational diabetes mellitus - A metabolic and reproductive disorder. Biomedicine and pharmacotherapy = Biomedicine and pharmacotherapy, 2021; 143:112183. Available from: https://doi.org/10.1016/j.biopha.2021.112183
5. Yang X, Yang C, Lu W. Berberine Suppresses Gestational Diabetes in Streptozotocin-induced Diabetes Mellitus Rats by Suppression of Inflammatory Mediators. Ind. J. Pharm. Edu. Res, 2023; 57(2):423-431.
de Mendonça E, Fragoso MB, de Oliveira JM, Xavier JA, Goulart MO, de Oliveira AC. Gestational Diabetes Mellitus: The Crosslink among Inflammation, Nitroxidative Stress, Intestinal Microbiota and Alternative Therapies. Antioxidants. 2022; 11(1):129. Available from: https://doi.org/10.3390/antiox11010129
Basu J, Datta C, Chowdhury S, Mandal D, Mondal NK, Ghosh A. Gestational Diabetes Mellitus in a Tertiary Care Hospital of Kolkata, India: Prevalence, Pathogenesis and Potential Disease Biomarkers. Exp Clin Endocrinol Diabetes. 2020; 128:216–223. Available from: https://doi.org/10.1055/a-0794-6057
Wang J, Zhu QW, Cheng XY, Sha CX, Cui YB. Clinical significance of neutrophil-lymphocyte ratio and monocyte–lymphocyte ratio in women with hyperglycemia. Postgrad Med. 2020; 132:702–708. Available from: https://doi.org/10.1080/00325481.2020.1764235
Camelo CW, Boggess K, Stürmer T, Brookhart MA, Benjamin DK, Jonsson FM. Association of Adverse Pregnancy Outcomes with Glyburide vs Insulin in Women with Gestational Diabetes. JAMA Pediatr: 2015; 169(18):1971-1977. Available from: https://doi.org/10.1001/jamapediatrics.2015.74
Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert opinion on investigational drugs, 2010;19(1):133-140. Available from: https://doi.org/10.1517/13543780903463862
Klein T, Fujii M, Sandel J, Shibazaki Y, Wakamatsu K, Mark M, Yoneyama H. Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis. Medical Molecular Morphology, 2014; 47:137-149. Available from: https://doi.org/10.1007/s00795-013-0053-9
Rosenstock J, Marx N, Neubacher D, Seck T, Patel S, Woerle HJ, et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology. 2015; 14(1). Available from: https://doi.org/10.1186/s12933-015-0215-2
Tradjenta [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; 2011
Akinlade, O.M., Owoyele, B.V. and Soladoye, A.O. Streptozotocin-induced type 1 and 2 diabetes in rodents: a model for studying diabetic cardiac autonomic neuropathy. African Health Scences.2021; 21(2):719-727. https://doi.org/10.4314/ahs.v21i2.30
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502. Available from: https://pubmed.ncbi.nlm.nih.gov/4337382/
American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes care, 41, S13–S27. Available from: https://doi.org/10.2337/dc18-s002
Zhou L, Zhang R, Yang S, Zhang Y, Shi D. Astragaloside IV alleviates placental oxidative stress and inflammation in GDM mice. Endocrine Connections, 2020; 9(9):939–945. Available from: https://doi.org/10.1530/ec-20-0295
Yu B, Liu Z, Fu Y, Wang Y, Zhang L, Cai Z, Yu F, Wang X, Zhou J, Kong W. CYLD Deubiquitinates Nicotinamide Adenine Dinucleotide Phosphate Oxidase 4 Contributing to Adventitial Remodeling. Arteriosclerosis, thrombosis, a vascular biology, 2017; 37(9):1698–1709. Available from: https://doi.org/10.1161/atvbaha.117.309859
Wani K, Sabico S, Alnaami AM, Al-Musharaf S, Fouda MA, Turkestani IZ, Al-Ajlan A, et al. Early-pregnancy metabolic syndrome and subsequent incidence in gestational diabetes mellitus in Arab women. Frontiers in Endocrinology. 2020; 11: 98. Available from: https://doi.org/10.3389/fendo.2020.00098
Abdel Aziz SM, Ahmed OM, Abd EL-Twab SM, Al-Muzafar HM, Amin KA, Abdel-Gabbar M. Antihyperglycemic Effects and Mode of Actions of Musa paradisiaca Leaf and Fruit Peel Hydroethanolic Extracts in Nicotinamide/Streptozotocin-Induced Diabetic Rats. Evidence-based Complementary and Alternative Medicine: 2020; 9276343. Available from: https://doi.org/10.1155/2020/9276343
Siddiqui N, Ali J, Parvez S, Zameer S, Najmi AK, Akhtar M. Linagliptin, a DPP-4 inhibitor, ameliorates Aβ (1−42) peptides induced neuro-degeneration and brain insulin resistance (BIR) via insulin receptor substrate-1 (IRS-1) in rat model of Alzheimer’s disease. Neuropharmacology. 2021; 195:108662. Available from: https://doi.org/10.1016/j.neuropharm.2021.108662
Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes, Obesity, and Metabolism. 2011; 13(3):258–67. Available from: https://doi.org/10.1111/j.1463-1326.2010.01350.x
Bohn MK, Adeli K. Physiological and metabolic adaptations in pregnancy: importance of trimester-specific reference intervals to investigate maternal health and complications. Critical reviews in clinical laboratory sciences, 2022; 59(2):76–92. Available from: https://doi.org/10.1080/10408363.2021.1978923
Zeljkovic A, Vekic J, Spasic S, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Gojkovic, T., Ardalic, D., Mandic-Markovic, V., Cerovic, N. and Mikovic, Z. Changes in LDL and HDL subclasses in normal pregnancy and associations with birth weight, birth length and head circumference. Maternal and Child Health Journal, 2013; 17(3): 556-565. Available from: https://doi.org/10.1007/s10995-012-1031-x
Reis SA, Conceição LL, Rosa DD, Siqueira NP, Peluzio MCG. Mechanisms responsible for the hypocholesterolaemic effect of regular consumption of probiotics. Nutrition research reviews, 2017; 30(1), 36–49. Available from: https://doi.org/10.1017/s0954422416000226
Zhou Y, Zhang X, Guo Y, Alarfaj AA, Liu J. Eupatilin mitigates Gestational diabetes in streptozotocin-induced diabetic pregnant rats through the regulation of inflammation and oxidative stress. Heliyon, 2024; 10(10): e30911.Available from: https://doi.org/10.1016/j.heliyon.2024.e30911
Al-Shehri SS. Reactive oxygen and nitrogen species and innate immune response. Biochimie, 2021; 181:52–64. Available from: https://doi.org/10.1016/j.biochi.2020.11.022
Zhang C, Yang Y, Chen R, Wei Y, Feng Y, Zheng W, Liao H, Zhang Z. Aberrant expression of oxidative stress-related proteins affects the pregnancy outcome of gestational diabetes mellitus patients. American journal of translational research, 2019; 11(1): 269–279. Available from: https://pubmed.ncbi.nlm.nih.gov/30787985/
Duan Y, Sun F, Que S, Li Y, Yang S Liu G. Prepregnancy maternal diabetes combined with obesity impairs placental mitochondrial function involving Nrf2/ARE pathway and detrimentally alters metabolism of offspring. Obes. Res. Clin. Pract. 2018; 12(2), 90–100. Available from: https://doi.org/10.1016/j.orcp.2017.01.002
Shen Z, Yang C, Zhu P, Tian C, Liang A. Protective effects of syringing against oxidative stress and inflammation in diabetic pregnant rats via TLR4/MyD88/NF-κB signaling pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020; 131: 110681. Available from: https://doi.org/10.1016/j.biopha.2020.110681
Ma Y, Xu S, Meng J, Li L. Protective effect of nimbolide against streptozotocin induced gestational diabetes mellitus in rats via alteration of inflammatory reaction, oxidative stress, and gut microbiota. Environ. Toxicol. 2022; 37:1382-1393. Available from: https://doi.org/10.1002/tox.23491
Li Y, Xi H, Zhang H. Protective effect of sinomenine against inflammation and oxidative stress in gestational diabetes mellitus in female rats via TLR4/ MyD88/NF κB signaling pathway. J. Food Biochem. 2021; 45, e13952.
Ayyasamy Rathinam, Leelavinothan Pari, Manigandan Venkatesan, Shankar Munusamy. Myrtenal attenuates oxidative stress and inflammation in a rat model of streptozotocin-induced diabetes. Archives of Physiology and Biochemistry, 2019. Available from: https://doi.org/10.1080/13813455.2019.1670212
Ide M, Sonoda N, Inoue T, Kimura S, Minami Y, Makimura H, et al. The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation. PLoS ONE. 2020; 15(2): e0228750. Available from: https://doi.org/10.1371/journal.pone.0228750